Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
4-week randomized double-blind placebo-controlled trial of SEP-363856 in acutely psychotic adults with schizophrenia
2016-001555-41Phase 2Completed
- Sponsor
- Sunovion
- Start
- Aug 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in schizophrenia comparing SEP-363856 with Placebo (2 arms). Primary endpoint: Change from baseline in PANSS total score at Week 4. Started Aug 2016; status: completed.
02
Drugs
ulotaront
03
Conditions
schizophrenia
Beyond the preview
Go deeper on 2016-001555-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-001555-41.